Načítá se...
Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections
Tedizolid phosphate is the first once-daily oxazolidinone approved by the United States Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections (ABSSSI). It is more potent in vitro than linezolid against methicillin-resistant Staphylococcus aureus (MRSA)...
Uloženo v:
| Vydáno v: | Infect Drug Resist |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4411017/ https://ncbi.nlm.nih.gov/pubmed/25960671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S56691 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|